Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors.

Publication Title

Advances in therapy

Authors

Philip Mease, Rheumatology Research, Providence Swedish Medical Center, Nordstrom Medical Tower, 1229 Madison St, Suite 1450, Seattle, WA, 98104, USA.Follow
Jessica A Walsh
Timothy P Fitzgerald
Soumya D Chakravarty
Elizabeth Adamson
Bruno Emond
Carmine Rossi
Samuel Schwartzbein
Kana Yokoji
Yuxi Wang
Patrick Lefebvre
Dominic Pilon
Shikha Singla
Joseph F Merola

Document Type

Article

Publication Date

11-21-2025

Keywords

Guselkumab; Interleukin-17A inhibitors; Psoriatic arthritis; Real-world; Treatment persistence.; washington; swedish

Abstract

INTRODUCTION: Patients with active psoriatic arthritis (PsA) initiating guselkumab are nearly two times more likely to remain persistent with on-label therapy at 12 months compared to those initiating subcutaneous (SC) interleukin-17A inhibitors (IL-17Ai). In this real-world study, on-label treatment persistence at 24 months was compared between patients with active PsA initiating guselkumab versus SC IL-17Ai, overall and among biologic-naïve and biologic-experienced subgroups.

METHODS: Adult patients with active PsA initiated on guselkumab or SC IL-17Ai (secukinumab, ixekizumab) between July 14 2020 and December 31 2022 were identified from the IQVIA PharMetrics

RESULTS: Overall, 849 patients initiating guselkumab (biologic-naïve: 362, biologic-experienced: 487) and 2601 patients initiating SC IL-17Ai (biologic-naïve: 845, biologic-experienced: 1756) were included. On-label treatment persistence rates at 24 months were 44.9% and 35.0% for patients initiating guselkumab or SC IL-17Ai, respectively, with patients initiating guselkumab being 1.49 times more likely to be persistent with on-label therapy (hazard ratio [95% confidence interval]: 1.49 [1.29, 1.72]; P <  0.001). Results were consistent among biologic-naïve (1.70 [1.32, 2.20]; P <  0.001) and biologic-experienced (1.33 [1.11, 1.59]; P = 0.002) subgroups.

CONCLUSION: This real-world study identified greater on-label treatment persistence rates at 24 months in patients with active PsA initiating guselkumab versus SC IL-17Ai, overall and among biologic-naïve and biologic-experienced subgroups.

Area of Special Interest

Orthopedics & Sports Medicine

Specialty/Research Institute

Orthopedics

Specialty/Research Institute

Rheumatology

DOI

10.1007/s12325-025-03416-z